ZOETIS INC

Explore Zoetis’s 2026 Form 4 filing: how short‑term share trades and a five‑year RSU plan align exec incentives with shareholder value.

Zoetis Q1 2026 highlights a 2.3 % revenue rise, AI‑driven biologic growth, and a ₹1.25/share dividend, underscoring strong cash flow and strategic partnerships.

Zoetis’ share slump hits a record low as investors fear its osteoarthritis therapy’s regulatory and safety hurdles.

Zoetis Inc. shares dip amid market downturn, yet solid safety data, proven efficacy, and an active regulatory pipeline hint at future upside. Investors should watch upcoming updates for potential rebounds.

Zoetis (ZTS) dips but retains strong momentum scores, suggesting short‑term volatility may hide long‑term upside in animal health & pharma.

Investor moves in Zoetis reveal how routine portfolio shifts reflect broader healthcare economics, showing value‑based pricing, tech ROI, and operational parallels for human care providers.

Zoetis’s $1.3 B Neogen genomics acquisition boosts precision veterinary medicine, enhancing diagnostics, reducing costs, and driving future growth.

Zoetis’s Q3 earnings miss reveals market saturation in companion‑animal sales, but the firm’s autogenous vaccine and Indian life‑sciences strategies offer untapped growth and higher margins.

Zoetis Q4 2025 results show modest earnings growth and a slightly higher 2026 outlook, yet shares dip amid U.S. companion‑animal competition, highlighting strategic shifts and future opportunities for animal health.

Zoetis beats Q4 2025 earnings, tops revenue and EPS forecasts, and ramps up biologics and companion‑animal vaccines, boosting FY‑2026 outlook.